Autopsy report · NCT04629196

Induction Optimization With Stelara for Crohn's Disease

“Other effective drugs have been introduced to market since the beginning of the study.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 3 months before it started.
• Ran for about 1 year 11 months before it stopped.
• 12 participants enrolled.
• Results were posted on the registry 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

NYU Langone Health

Sponsor type

University, hospital or other

Conditions

Crohn Disease

Interventions

Ustekinumab; Ustekinumab; Ustekinumab

Participants

12

Sites

2

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.